Introduction:
Sanofi Pasteur announced its US$ 410 million investment plan for the construction of a new state-of-the-art vaccine manufacturing facility centre at its Canadian headquarters in Toronto.
Features:
The new facility will allow Sanofi Pasteur to increase its capacity to meet the growing demand of five-component acellular pertussis (5-acP) antigen and come one step closer in reducing the number of deaths caused due to vaccine-preventable disease.
The New Toronto Vaccine facility centre is planned to get completed by 2021.
It will be one of the largest investments ever made by Sanofi in a single building which will also have the facility to produce the antigens used in diphtheria and tetanus vaccines.
Specifications:
| Name | Sanofi Pasteur |
| Location | Toronto, Ontario |
| Type | Expansion |
| Estimated Budget | US$410 million |
| Parties Involved | Sanofi Pasteur |
| Schedule | 2021 |
